Study of CAL101, which targets a novel upstream pathway implicated in fibrotic disease, enrolls 161 patients more than six months ahead of plan; topline data expected Q1 2027 Drug candidate, a ...
OSLO, Norway--(BUSINESS WIRE)--Calluna Pharma AS (Calluna), a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory and fibrotic diseases, today announced the ...
Add as a favourite source on Google Add DutchNews as a favourite source on Google Clinical stage company formed from the merger of Oxitope Pharma and Arxx Therapeutics Calluna Pharma has a pipeline of ...
Oxitope Pharma and Arxx Therapeutics have announced their merger to form Calluna Pharma, which has raised €75m in a series A financing, to develop novel therapies for immunological diseases. The new ...
CAL101 is a first-in-class monoclonal antibody targeting S100A4, a damage-associated molecular pattern (DAMP) protein associated with serious and life-threatening fibrotic disorders Phase 2 AURORA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results